Vaccine Alarm: Study Unveils Serious Health Risks After COVID-19 Inoculation

by Jessica

The Global Vaccine Data Network (GVDN) spearheaded a groundbreaking multinational study, unearthing valuable insights into the safety of COVID-19 vaccines and revealing potential health risks among a cohort of 99 million vaccinated individuals.

This groundbreaking research, spanning multiple countries, aimed to evaluate adverse events of special interest (AESI) following COVID-19 vaccination, providing vital information regarding vaccine safety.

The study, published by Elsevier, a leading scientific publisher and data analytics company, has sparked considerable attention due to its comprehensive analysis of adverse events associated with COVID-19 vaccination.

Countries included in the study range from Denmark and New Zealand to Argentina and Canada, encompassing diverse populations and vaccine distribution strategies.

With meticulous detail, researchers scrutinized the administration of 183,559,462 doses of Pfizer (BNT162b2), 36,178,442 doses of Moderna (mRNA-1273), and 23,093,399 doses of Oxford/AstraZeneca (ChAdOx1) vaccines across various demographics.

By examining adverse events reported post-vaccination, the study aimed to identify any potential safety concerns associated with COVID-19 vaccines, as reported by Raw Story on Monday, February 19, 2024.

Among the health issues scrutinized were neurological conditions, blood clotting disorders, and heart-related complications, all of which have been subjects of heightened scrutiny amid ongoing vaccination campaigns.

Through a standardized system of medical codes known as ICD-10, researchers meticulously documented adverse events to discern any patterns or anomalies.

The findings of the study revealed several noteworthy observations regarding adverse events following COVID-19 vaccination.

Notably, an increased incidence of Guillain-Barré syndrome (GBS), a rare nerve disorder, was observed following the first dose of the Oxford/AstraZeneca vaccine.

Additionally, acute disseminated encephalomyelitis (ADEM), a rare inflammatory condition affecting the brain and spinal cord, manifested more frequently after the first dose of the Moderna vaccine.

Furthermore, the study highlighted concerning trends in blood clotting disorders, with the Oxford/AstraZeneca vaccine associated with elevated instances of cerebral venous sinus thrombosis (CVST), a type of blood clot in the brain.

Instances of low platelet counts and pulmonary embolism, indicative of potential clotting issues, were also reported following the administration of various COVID-19 vaccines.


In the realm of heart-related complications, cases of myocarditis and pericarditis, inflammation of the heart muscle and outer layer respectively, were significantly higher than expected following doses of mRNA vaccines, such as Pfizer and Moderna.

These findings underscored the importance of monitoring cardiovascular health post-vaccination and raised important safety signals that warrant further investigation.

While the study provided valuable insights into adverse events following COVID-19 vaccination, it also emphasized the importance of ongoing surveillance and monitoring of vaccine safety.

By identifying potential risks associated with vaccination, researchers can inform public health policies and interventions aimed at mitigating adverse outcomes and ensuring the continued safety of vaccination campaigns.


Related Posts